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نسخة معدلة من مؤشر األعراض جوف
أداة بسيطة لتصنيف حاالت سرطان املبيض
جيوثي �ستي، بريادار�سيني، ديك�سا باندي، ماجنوناث
abstract: Objectives: Ovarian cancer often goes undiagnosed or misdiagnosed in the early stages. The present 
study aimed to validate a modified version of the Goff Symptom Index (GSI) in an Indian population. Methods: 
This prospective case-control study was conducted between July 2010 and June 2012 in a university hospital in 
Manipal, Karnataka, India. A total of 305 inpatients admitted for ovarian pathology investigations and outpatients 
undergoing routine gynaecological check-ups were included in the study. The modified GSI (MGSI) was used to 
investigate the presence, severity, frequency and duration of 10 ovarian cancer symptoms on a scale of 1–5. Four 
additional symptoms were included with those of the original GSI (two symptoms from a previous MGSI and two 
new symptoms). Patients were regarded as positive for ovarian cancer if symptoms occurred >12 times per month 
and time since onset was <1 year. Histopathology confirmed the diagnosis of ovarian tumours. Results: A total of 
13 patients were excluded. The final sample (n = 292) was divided into a test group (n = 74) and a control group 
(n = 218) based on histopathology. Within the controls, 144 women were found to have benign tumours. The MGSI 
was positive in 71.6% of the test group as opposed to only 11.5% of the control group. The addition of two symptoms 
(loss of appetite and weight) to the GSI increased the test’s sensitivity from 71.6% to 77% without compromising 
specificity (88.5%). Conclusion: Based on these findings, the addition of two new symptoms (loss of appetite and 
weight) to the GSI is proposed in order to increase the test’s sensitivity. However, the addition of urinary symptoms 
to the GSI requires further validation.
Keywords: Ovarian Cancer; Diagnosis; Symptom Assessment; Triage; Algorithm; Reliability and Validity; India.
امللخ�ص: الهدف: غالبا ما ل يتم ت�سخي�س �رسطان املبي�س اأو ي�سخ�س ب�سكل خاطئ يف املراحل املبكرة. تهدف هذه الدرا�سة اإىل التحقق 
من �سحة ا�ستخدام ن�سخة معدلة من موؤ�رس الأعرا�س جوف )GSI( يف ال�سكان الهنود. الطريقة: اأجريت هذه الدرا�سة على حالت مر�سية 
و�سوابط بني يوليو 2010 ويونيو 2012 يف م�ست�سفى اجلامعة يف مانيبال، كارناتاكا، الهند. اأدرجت يف هذه الدرا�سة 305 حالة من حالت 
اأمرا�س املبي�س املختلفة و�سوابط ت�سمل ن�ساء ياأتني لفحو�سات اأمرا�س ن�ساء روتينية يف العيادات اخلارجية. ا�ستخدمت ن�سخة معدلة 
من موؤ�رس الأعرا�س جوف )MGSI( للتاأكد من وجود و�سدة وتكرار ومدة 10 اأعرا�س من �رسطان املبي�س على مقيا�س من 5-1. واأدرجت 
اإذا حدثت الأعرا�س  اإيجابية ل�رسطان املبي�س  GSI. اعتربت احلالت  األعرا�س جوف  اأربعة اأعرا�س جديدة مع تلك املدرجة على موؤ�رس 
13 مري�سة من الدرا�سة  النتائج: مت ا�ستبعاد  اأورام املبي�س.  1< �سنة.واأكد الت�سخي�س املجهري  12> مرة يف ال�سهر منذ بداية الأعرا�س 
الت�سخي�س املجهري. �سمن  اأ�سا�س  عدد 218 على  ال�سابطة  عدد 74 واملجموعة  اإىل جمموعة اختبار  عدد 292  النهائية  العينة  ثم  تق�سيم 
ال�سوابط، مت العثور على 144 من الن�ساء لديهم اأورام حميدة. كان MGSI اإيجابيا يف %71.6 من جمموعة الختبار يف مقابل %11.5 فقط 
من املجموعة ال�سابطة. اإ�سافة اثنني من الأعرا�س )فقدان ال�سهية والوزن( اإىل GSI زادت ح�سا�سية الختبار من %71.6 اإىل %77 دون 
امل�سا�س بخ�سو�سية الختبار )%88.5(. اخلال�صة: ا�ستنادا اإىل هذه النتائج، يقرتح اإ�سافة اثنني من الأعرا�س اجلديدة وهي )فقدان ال�سهية 
والوزن( اإىل GSI من اأجل زيادة ح�سا�سية الختبار. واإ�سافة الأعرا�س البولية ملوؤ�رس الأعرا�س يتطلب مزيدا من التحقق من �سحة الختبار.
مفتاح الكلمات: �رسطان املبي�س؛ الت�سخي�س؛ تقييم اأعرا�س؛ ت�سنيف؛ النظم؛ ال�سحة والدقة؛ الهند.
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Simple triage tool for ovarian malignancy
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Advances in Knowledge
- Early-stage ovarian malignancies often go unnoticed or misdiagnosed. This study emphasises the importance of using a simple index 
based on the common non-specific symptoms of ovarian cancer.
- This study may be a platform for further population-based studies to determine the benefit of this simple index in screening women for 
early-stage ovarian malignancies.
Applications to Patient Care 
- The modified symptom index was found to be helpful in identifying women with early-stage ovarian cancer among a sample in India.
- The identified clusters of non-specific symptoms in the proposed symptom index can assist women in self-screening and help family 
physicians to make timely patient referrals.
- Health workers and the general population should be made aware of the common non-specific symptoms of ovarian cancer in order to 
minimise delay in diagnosis.
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Ovarian cancer remains a majorhealth concern worldwide, with more than 225,000 new cases annually leading 
to 140,000 deaths.1,2 Ovarian cancer often goes 
unnoticed or misdiagnosed in its early stages. Hence, 
many researchers have evaluated the predictive value 
of ovarian cancer symptoms.3–5 Recent research has 
also emphasised the highly stressful effect of a late 
ovarian cancer diagnosis on quality of life.6 Screening 
strategies like sonography and cancer antigen (CA) 
125 tests have failed to prove their efficacy in early 
detection among the general population.7 
The recognition of non-specific symptoms of the 
disease may minimise diagnostic delays, facilitate 
early management and improve survival rates. A 
thorough understanding of the spectrum of non-
specific symptomatology in ovarian malignancies 
can help in making an early diagnosis. The other 
advantage of using a symptom-based screening tool is 
to create awareness among the general public. Thus, 
the potential utility of recognising unique patterns of 
non-specific symptoms is two-fold—such recognition 
can alert both patients and healthcare providers to 
potential ovarian malignancies.8 The present study 
was conducted with the aim of validating Kim et al.’s 
modified version of the Goff Symptom Index (GSI) 
in an Indian population.9,10 Furthermore, this study 
sought to validate the addition of two new symptoms 
to Kim et al.’s modified GSI (MGSI).10
Methods
This prospective case-control study was conducted 
between July 2010 and June 2012 in a university 
hospital in Manipal, Karnataka, India. A total of 305 
women were enrolled in this study. This included 
both women who were admitted to the hospital 
for evaluation and management of ovarian tumour 
pathology and those with an intact uterus and at 
least one intact ovary who visited the outpatient 
department for a routine gynaecological check-up 
during the study period. The latter patients formed the 
control-clinic group.
All of the participants were given a survey to 
complete. The survey instrument was specifically 
designed for the current study and included questions 
eliciting demographic information, such as age, 
number of children and body mass index. The 
remainder of the survey investigated the presence, 
severity, frequency and duration of 10 ovarian cancer 
symptoms. These included six symptoms (pelvic pain, 
abdominal pain, increased abdominal size, bloating, 
difficulty in eating and a feeling of fullness) from the 
original symptom index proposed by Goff et al.9 Two 
other symptoms (urinary urgency and frequency) were 
included, as proposed by Kim et al. in the MGSI.10 
Finally, two new symptoms (loss of weight and loss 
of appetite) were also included, based on the authors’ 
past experience with ovarian cancer cases. 
The participants were asked to rate the severity of 
each of these 10 symptoms on a scale of 1–5, with a 
score of 1 being mild and 5 being intolerable. Similar 
scales were used to determine the frequency and 
duration of each symptom. Eight symptoms, excluding 
the two new symptoms, were combined into four 
symptom clusters (abdominal/pelvic pain, increased 
abdominal size/bloating, difficulty in eating/feeling 
full and urinary frequency/urgency). The symptom 
index was considered to be positive for ovarian cancer 
if any of these symptoms occurred >12 times a month 
and the total duration since the onset of the symptom 
was <1 year. In order to avoid bias, the investigator 
involved with data collection remained unaware of the 
patients’ diagnoses during the survey period. 
 Following their completion of the survey, all of the 
participants who presented with ovarian pathology 
underwent post-surgical histopathological assessment 
of their ovarian tumours. As the control-clinic group 
had no ovarian pathology, they did not undergo any 
histological assessment. If a post-surgical (following 
a cystectomy, ovariotomy or staging laparotomy) 
histopathology report revealed a borderline ovarian 
tumour, these patients were excluded from the final 
analysis. Participants with ovarian malignancies 
revealed by histopathology were assigned to the test 
group, while those with benign ovarian neoplasms or 
endometriomas were classified as the control-benign 
group. Participants were therefore assigned to one of 
two groups (test group or control group), with those 
in the control group further classified according to two 
subgroups (control-benign and control-clinic groups). 
The inclusion of a control-clinic group helped ensure 
the test and control-benign groups were comparable. 
A comparative analysis was performed between 
the results of the survey and the final diagnoses for 
all participants. As no histological examinations were 
performed for the control-clinic group, transvaginal 
sonography suggestive of a normal ovarian architecture 
was taken to indicate no pathology. Statistical analysis 
was performed using the Statistical Package for the 
Social Sciences, Version 16.0 (IBM Corp., Chicago, 
Illinois, USA). Symptoms were compared using a 
Chi-squared test. The odds ratio of each symptom 
was calculated by logistic regression analysis. A multi-
variate logistic regression was performed to determine 
which of the four symptom clusters remained 
independently significant. For all analyses, P <0.05 was 
considered statistically significant. 
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Ethical approval for this study was granted by the 
Institutional Ethics Committee of Kasturba Hospital, 
Manipal, India (#IEC124/2010). Written informed 
consent was obtained from all participants before 
inclusion in the study. 
Results
Of the 305 women enrolled in the study, 304 completed 
the survey (response rate: 99.7%). A total of 12 patients 
were excluded from the final analysis (seven from the 
test group and five from the control-benign group) 
as their final histopathology assessments revealed 
borderline ovarian tumours. Thus, the final cohort 
consisted of 292 women [Figure 1]. Of these, 74 made 
up the test group while 218 made up the control group. 
For the latter group, the women were subdivided into a 
control-benign subgroup (n = 144) and control-clinic 
subgroup (n = 74). The demographic characteristics of 
the cohort are presented in Table 1.
The symptom index was positive for ovarian cancer 
for 71.6% of women in the test group as opposed to only 
11.5% of women in the control group. This difference 
was statistically significant (P <0.001). The majority 
of clustered symptoms were reported to occur more 
frequently among the test group in comparison to 
the control group, including abdomen/pelvic pain 
 
Figure 1: Figure 1: CONSORT (Consolidated Standards of Reporting Trials) flow chart detailing the population of the 
current hospital-based prospective case-control study.
*Diagnosis of malignant ovarian tumours were based on clinical features.
Table 1: Demographic characteristics reported among 

































































































BMI = body mass index.
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(44.6% versus 7.8%), increased abdominal size/bloating 
(55.4% versus 6.0%) and difficulty in eating/feeling full 
(45.9% versus 3.2%). These three symptom clusters were 
statistically significant predictors of ovarian cancer 
according to the histopathological findings [Table 2]. 
Urinary symptoms were not indicated among 
any women in the test group. In contrast, three 
women in the control group complained of urinary 
frequency/urgency. While one patient in the test 
group complained of increased urinary frequency, 
the total duration since the onset of the symptom was 
>1 year. As urinary symptoms were absent from 
the test group, this symptom cluster was excluded 
from the logistic regression analysis. All of the other 
symptom clusters were independent predictors of 
ovarian cancer according to the logistic regression 
analysis [Table 3]. 
In the test group, there were six patients with 
stage IV ovarian cancer, 43 with stage III, six with 
stage II and 17 with stage I. Two patients were not 
staged as one had a Krukenberg tumour and the other 
had synchronous endometrial cancer. A total of 60 
patients had epithelial cancer, seven had germ cell 
cancer, six had sex cord-stromal tumours and one had 
a Krukenberg tumour. 
The results of the symptom index were analysed 
according to cancer stage among individuals in the test 
group. The symptom index was found to be positive 
in 83.3% of stage IV patients and 76.7% of stage III 
patients. However, it was also positive in 64.7% and 50% 
of those with stage I and stage II cancer, respectively. 
On correlating the symptom index with histology 
findings, the symptom index was found to be positive 
among 78% of those with epithelial cancer, 71.5% of 
those with germ cell cancer and 16.6% of those with 
sex cord-stromal tumours. 
A total of 21 patients in the test group had 
negative symptom index results. Of these, seven 
experienced abdominal pain and one had bloating; 
however, these symptoms occurred <12 times a 
month. Four patients experienced a loss of appetite 
and weight, four presented with menstrual irregulari-
ties, two presented with postmenopausal bleeding, 
one reporting having backache and two developed 
features of hyperandrogenism. In terms of histology, 
a negative symptom index was reported by 16.3% of 
those with epithelial cancer, 28.6% of those with germ 
cell tumours, 83.3% of those with sex cord-stromal 
tumours and 100% of those with a Krukenberg tumour. 
The clinical significance of each symptom cluster 
was calculated in terms of sensitivity, specificity 
and positive and negative predictive values. Increased 
abdominal size and bloating were the most sensitive 
symptoms (55.4%). Although the sensitivity of individual 
clusters was approximately 50%, adding them together 
resulted in the sensitivity of the index increasing to 
71.6% [Table 4]. 
The new symptom cluster added to the MGSI (loss 
of appetite and weight) was one of the most common 
clusters reported among women with ovarian cancer. 
A total of 34 women (45.9%) in the test group reported 
having these symptoms. The addition of these two 
symptoms to the MGSI was therefore compared to the 
MGSI in terms of sensitivity and specificity [Table 5]. 
Adding this symptom cluster to the modified symptom 
index increased the sensitivity of the test from 71.6% 
to 77%, without compromising the specificity, which 
remained at 88.5%. 
Table 2: Positive modified Goff Symptom Index10 
for ovarian malignancy and distribution of symptom 
clusters reported among test and control groups at an 
Indian university hospital (N = 292)












































*The symptom index was considered to be positive for ovarian cancer if 
any symptoms were reported to have occurred >12 times a month and 
total duration since the onset of the symptom was <1 year.
Table 3: Independent logistic regression analysis of 
the Goff Symptom Index9 for ovarian malignancy and 
symptom clusters reported among test and control 
groups at an Indian university hospital (N = 292)









Difficulty in eating/feeling 
full
26.6 10.61–61.82 <0.001
Positive* Goff Symptom 
Index9
19.5 10.12–37.50 <0.001
OR = odds ratio; CI = confidence interval.
*The symptom index was considered to be positive for ovarian cancer if 
any symptoms were reported to have occurred >12 times a month and 
total duration since the onset of the symptom was <1 year.
Modified Goff Symptom Index 
Simple triage tool for ovarian malignancy
e374 | SQU Medical Journal, August 2015, Volume 15, Issue 3
was considered positive for ovarian cancer if any of 
those six symptoms occurred >12 times per month 
and had been present for <1 year. In the confirmatory 
sample, the index had a sensitivity of 56.7% and 79.5% 
for early- and advanced-stage cases, respectively.9 
Specificity was 90% for women >50 years of age and 
86.7% for women <50 years of age.9 This original 
symptom index was found to be an effective triage 
tool for ovarian malignancies in the current studied 
cohort of Indian women. Patients with a positive 
symptom index should therefore be referred to an 
appropriate medical centre for an evaluation of 
potential ovarian cancer.
Kim et al. supported the efficacy and validity of 
the GSI in a Korean population, with sensitivity and 
specificity rates of 65.5% and 84.7%, respectively.10 Two 
urinary symptoms (urgency/frequency) were added 
to the original GSI and found to be an independent 
predictor of ovarian cancer.10 However, the two urinary 
symptoms added by Kim et al. in the MGSI were not 
an important predictor of ovarian malignancy in the 
current study. Urinary symptoms were not common 
among the studied Indian cohort, perhaps due to the 
younger median age of the test group and smaller 
tumour sizes. Urinary symptoms were also not 
included by Goff et al. in their index as addition of 
these symptoms did not result in improved sensitivity 
of the index.9 Thus, further research is required to find 
the significance of this particular symptom cluster 
before including it among future ovarian cancer 
symptom indexes.
In the current study, the two new symptoms 
added—loss of appetite/weight—were found to be 
significantly present in the test group. Furthermore, 
when this symptom cluster was included, the sensitivity 
of the index increased by 5.4% without compromising 
the specificity of the test. These results suggest that 
this variable should be added to the original index 
proposed by Goff et al.9 Although borderline ovarian 
tumours were excluded from the final analysis, a 
Discussion
Ovarian cancer cases have a high frequency of late 
diagnosis and associated mortality.11 As a result, there 
is a dire need to focus research on effective methods of 
screening for and detecting ovarian cancer at an early 
stage. Unfortunately, no screening test or surveillance 
strategy to date has achieved this goal. Van Nagell et 
al. determined that neither sonography nor CA 125 
testing were cost-effective or practical for ovarian 
cancer screening in the general population, revealing 
that 5,200 ultrasound scans were needed in order to 
detect one case of invasive cancer.12 Furthermore, 
even when assessing cancer incidence among a high-
risk cohort, Liede et al. reported that the combination 
of sonography and CA 125 testing did not prove 
efficacious in reducing mortality or morbidity.13 
After exploring the symptomatology of ovarian 
cancer patients, Goff et al. noted that women with 
ovarian cancer frequently reported symptoms prior to 
diagnosis, although these symptoms were usually non-
specific.14,15 Based on the hypothesis that recognition 
of this symptom pattern would serve as a simple and 
cost-effective screening tool, Goff et al. proposed their 
original symptom index in 2007.9 The original GSI 
included six symptoms clustered into three groups 
(pelvic/abdominal pain; increased abdominal size/
bloating; and difficulty in eating/feeling full).9 The GSI 
Table 4: Clinical efficacy of individual symptom clusters 
and the modified Goff Symptom Index10 in predicting 
ovarian malignancy among test and control groups at 
an Indian university hospital (N = 292)
Variable Percentage























71.6 88.5 67.9 90.1
PPV = positive predictive value; NPV = negative predictive value.
*The symptom index was considered to be positive for ovarian cancer if 
any symptoms were reported to have occurred >12 times a month and  
total duration since the onset of the symptom was <1 year.
Table 5: Clinical efficacy of the modified Goff Symptom 
Index10 for ovarian malignancy and the same index 
with two new additional symptoms (loss of appetite 
and weight) among test and control groups at an Indian 




Sensitivity Specificity PPV NPV
MGSI10 71.6 88.5 67.9 90.1
Current 
index*
77.0 88.5 69.5 91.9
MGSI = modified Goff Symptom Index; PPV = positive predictive 
value; NPV = negative predictive value.
*Addition of two new symptoms (loss of appetite and loss of weight) to 
the MGSI proposed by Kim et al.10 
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subanalysis of this group showed the symptom index 
to be positive in 11 out of 12 cases (91.6%). 
To the best of the authors’ knowledge, this is the 
first study to correlate a symptom index with 
histological types of ovarian malignancies. The 
symptom index used in the current study was found 
to hold well for epithelial cancer and, to some extent, 
for germ cell tumours. However, the role of this 
symptom index in detecting sex cord-stromal and 
Krukenberg tumours was found to be limited. This may 
be because sex cord-stromal tumours present early 
due to bleeding and symptoms related to an altered 
hormonal milieu, unlike epithelial ovarian cancers.16 
Hoskins et al. reported that only 15% of women in 
their study were familiar with the symptoms of ovarian 
cancer.17 Creating awareness of these symptoms 
with an emphasis on the frequency and duration of 
individual symptoms could influence women to seek 
healthcare advice earlier, thus minimising diagnostic 
delays and reducing mortality related to late diagnoses. 
The early detection of ovarian cancer will be much less 
difficult when well-informed women work in tandem 
with clinicians. 
The results of the current study should be 
interpreted in light of some limitations. The population 
was heterogeneous and included a small number of 
patients. Additionally, this was a hospital-based study 
and the results may therefore not be representative of 
the Indian population in general. 
Conclusion
The original GSI was an effective triage tool in the 
studied cohort of Indian women and the results 
supported the value of an ovarian cancer symptom 
index which can be used among women with non-
specific symptoms. Furthermore, the addition of 
two new symptoms (loss of appetite/weight) to the 
MGSI increased the sensitivity of the test, without 
diminishing specificity. However, the two urinary 
symptoms of the MGSI were not found to be an 
important predictor of ovarian malignancy. Further 
research is needed to assess the efficacy of including 
these symptoms in the GSI. Awareness of ovarian 
cancer symptoms should be promoted among health 
workers as well as the general population in order 
to minimise delays in diagnosis and treatment of 
ovarian cancer. 
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